Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
Completed · Phase 2
Conditions studied: Clostridium Difficile Infection
In brief
The objective of this Phase IIa study is to assess the safety, tolerability, and efficacy of incremental doses of MGB-BP-3 in patients with Clostridium difficile-associated diarrhea (CDAD).
Key facts
- Study ID
- NCT03824795
- Run by
- MGB Biopharma Limited
- People needed
- 34
- Starts
- 2019-02-07
- Expected to finish
- 2020-04-03
- Last updated by the study team
- 2020-04-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Florida International Medical Research — Miami, Florida, United States
- Omega Research Maitland LLC — Orlando, Florida, United States
- Snake River Research PLLC — Idaho Falls, Idaho, United States
- Ochsner Clinic Foundation Infectious Disease Research — New Orleans, Louisiana, United States
- Anne Arundel Medical Centre — Annapolis, Maryland, United States
- Mercury Street Medical Group PLLC — Butte, Montana, United States
- Biopharma Informatic LLC — Houston, Texas, United States
- Verity Research Inc. — Fairfax, Virginia, United States
- Foothills Medical Centre — Calgary, Alberta, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.